A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma

Lin, Xixi; Yang, Sijie

doi:10.17219/acem/149566

Cited by 10 publications

(9 citation statements)

References 44 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The AC009549.1, AL136419.3 has been reported to associated with progression and prognosis in colorectal cancer, head and neck squamous cell carcinoma, [29,30] . The AL928654.1, MKLN1-AS, TMCC1-AS1 were found as lncRNAs related to the progression of HCC [31][32][33] , while AC138696.2, AL449106.1 have not been studied yet. Subsequently, HCC patients were separated into high-and low-risk groups based on the intermediate risk score, and the high-risk group had apparently poor clinical results.…”

Section: Discussionmentioning

confidence: 99%

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

Ma,

Liu,

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Disulfidptosis is a newly discovered mechanism of programmed cell death. However, the role of disulfidptosis - related lncRNAs (DRlncRNAs) in HCC remains unclear. The purpose of this study is to establish the prognostic model of DRlncRNAs and explore its prognostic value in HCC. Materials and methods: The relevant clinical data and RNA-seq were obtained from the Cancer Genome Atlas (TCGA) database. The DRlncRNAs were identified via univariate and multivariate Cox regression, lasso algorithm analysis, and then established the prognostic model. Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, principal component analysis (PCA), univariate and multivariate Cox regression analysis, functional enrichment annotation and the nomogram were used to assess the reliability of risk model. Furthermore, the potential immunotherapeutic signatures and drug sensitivity prediction were also performed. The RT-qPCR was applied to identify the expression of DRlncRNAs. Results:We constructed a prognostic model with 7 DRlncRNAs and proved the model could well predict the survival and prognosis of HCC patients. Immune correlation analysis suggested that low-risk patients had better immunotherapeutic outcomes. Drug prediction showed that Erlotinib, Gefitinib, Savolitinib, Osimertinib, Lapatinib, Afatinib and Crizotinib were more effective in low-risk patients; Sorafenib, Selumetinib, and Axitinib were more effective in high-risk patients. Finally, the expression of DRlncRNAs in normal liver and HCC cell lines were testified by RT-qPCR. Discussion and Conclusions: We constructed a risk model and provided a new direction for diagnosing and treating HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

Ma,

Liu,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…All these lincRNAs played essential roles in HCC biological process. Studies showed that lncRNA AC012073.1 played an oncogenic role in influencing HCC prognosis and was associated with N6-methyladenosine and ferroptosis (40,41). AL031985.3 was associated with pyroptosis, immune response, ferroptosis, glycolysis, and autophagy in HCC (42)(43)(44)(45).…”

Section: Discussionmentioning

confidence: 99%

“…Currently, many studies are focused on precision genomic medicine, and many predictive models have been developed in an attempt to predict patient outcomes. Many lncRNAs, like N6methyladenosine-related lncRNAs, ferroptosis-related lncRNAs, pyroptosis-related lncRNAs, glycolysis-Related lncRNAs, contributed to a better understanding of HCC biological processes and helped predict the prognosis of HCC (40)(41)(42)(43)(44)(45). However, few studies concentrated on CD4+ Tconv-related lncRNAs, and the roles of CD4+ Tconv-related lncRNAs remained unclear.…”

Section: Discussionmentioning

confidence: 99%

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Zhu

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and CD4+ T lymphocytes can inhibit hepatocarcinogenesis and mediate tumor regression. However, few studies have focused on the prognostic power of CD4+ Tconv-related lncRNAs in HCC patients.MethodWe obtained data from TCGA and GEO databases and identified CD4+Tconv-related lncRNAs in HCC. The risk score was constructed using lasso regression and the model was validated using two validation cohorts. The RS was also assessed in different clinical subgroups, and a nomogram was established to further predict the patients’ outcomes. Furthermore, we estimated the immune cell infiltration and cancer-associated fibroblasts (CAFs) through TIMER databases and assessed the role of RS in immune checkpoint inhibitors response.ResultsWe constructed a CD4+ Tconv-related lncRNAs risk score, including six lncRNAs (AC012073.1, AL031985.3, LINC01060, MKLN1-AS, MSC-AS1, and TMCC1-AS1), and the RS had good predictive ability in validation cohorts and most clinical subgroups. The RS and the T stage were included in the nomogram with optimum prediction and the model had comparable OS prediction power compared to the AJCC. Patients in the high-risk group had a poor immune response phenotype, with high infiltrations of macrophages, CAFs, and low infiltrations of NK cells. Immunotherapy and chemotherapy response analysis indicated that low-risk group patients had good reactions to immune checkpoint inhibitors.ConclusionWe constructed and validated a novel CD4+ Tconv-related lncRNAs RS, with the potential predictive value of HCC patients’ survival and immunotherapy response.

show abstract

“…Ferroptosis is a unique pattern of cell death that has received extensive interest, especially in the area of tumorigenesis and therapies [29]. Several research studies have mainly concentrated on developing DEFRlncRNA signatures to assess the prognosis of tumor patients [16,18,[30][31][32]. Nevertheless, the vast majority of signatures are established on the basis of the expression levels of quantitative transcripts.…”

Section: Discussionmentioning

confidence: 99%

Identification of Ferroptosis-Related lncRNA Pairs for Predicting the Prognosis of Head and Neck Squamous Cell Carcinoma

Wu¹,

Liu

Chen

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Ferrogenesis was strongly associated with tumorigenesis and development, and activating the ferrogenic process was a novel regimen in treating cancer, especially conventional treatment-resistant cancers. The purpose of the article was to construct a ferroptosis-related long noncoding RNAs (FRlncRNAs) signature, regardless of expression levels to effectively predict prognosis and immunotherapeutic response for head and neck squamous cell carcinoma (HNSCC). Methods. The RNA-seq data for HNSCC and corresponding clinical information were obtained in the TCGA database, and ferroptosis-related genes (FRGs) were extracted in the ferroptosis database. On this basis, differentially expressed FRlncRNAs (DEFRlncRNAs) pairs were identified through coexpression analysis, differential expression analysis, and a fresh pairing algorithm. Then, a risk assessment model was established with univariate Cox, LASSO, and multivariate Cox regression analysis. Finally, we evaluated the model from various aspects, including survival status, clinicopathological characteristics, infiltration status of immune cells, immune functions, chemotherapeutic sensitivity, immune checkpoint inhibitors (ICIs)-related molecules, and N6-methyladenosine (m6A) mRNA status. Result. We established a signature of 11-DEFRlncRNA pairs related to the prognosis of HNSCC that had AUC values above 0.75 in the one-, three-, and five-year ROC curves, underscoring the high susceptibility and specifiability of predicting HNSCC prognosis. Survival rates were remarkably higher for the low-risk patients than for the high-risk patients, and the signature was significantly correlated with survival, clinical, T, and N stages. Finally, immune cell infiltration status, immune functions, chemotherapeutic sensitivity, and expression levels of ICIs-related and m6A-related molecules were statistically different among different groups. Conclusion. Our study established a novel lncRNA signature, which is independent of specific expression levels, could predict patient prognosis, and might have promising clinical applications in HNCSS.

show abstract

A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma

Cited by 10 publications

References 44 publications

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

Disulfidptosis-related lncRNAs are potential biomarkers for predicting prognoses in patients with hepatocellular carcinoma

Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment

Identification of Ferroptosis-Related lncRNA Pairs for Predicting the Prognosis of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About